<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62091">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01928836</url>
  </required_header>
  <id_info>
    <org_study_id>CAALC-001-LCBP</org_study_id>
    <nct_id>NCT01928836</nct_id>
  </id_info>
  <brief_title>Risk Stratification of Patients Using the Lung Cancer Biomarker Panel in China</brief_title>
  <acronym>LCBP</acronym>
  <official_title>Multicenter Study for Risk Stratification of Patients Presenting With Symptoms Related to Lung Cancer Using the Lung Cancer Biomarker Panel (LCBP) in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bai Chunxue</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanjing PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Third Military Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henan Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Alliance Against Lung Cancer</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to verify clinical utility of a simple blood test comprising of
      four protein- based markers for risk stratification of patients presenting symptoms related
      to lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a multicenter, prospective case-control research. Totally 1,200 cases will be
      collected in the hospitals, with 600 cases in control group, which are not suspected as lung
      cancer from chest CT, and other 600 in suspected group. When inclusion into the two groups,
      clinical information and 10mL blood sample of the patient will be recorded and tested for
      cancer biomarkers, biochemical detection and cardiovascular disease biomarkers, etc. The
      correlation between cancer biomarker panel, CT scan result and clinical pathological
      diagnosis will be investigated through cases follow up. The sample size estimated above was
      set up according to sensitivity and specificity of biomarkers in pre-study, based on lung
      cancer incidence of the population. To compare the diagnostic accuracy among different
      cancer biomarkers through T-test, Mann-Whitney U and receiver operating characteristic (ROC)
      curve with SPSS 15.0 software. In statistic analysis, 0.05 is set as the p value for
      significance. Effectiveness of the four biomarkers panel in lung cancer diagnoses and
      staging will be analyzed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Incidence rate of lung cancer</measure>
    <time_frame>Up to 1 year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Lung Neoplasms</condition>
  <arm_group>
    <arm_group_label>Non-suspected lung cancer group</arm_group_label>
    <description>Aged 40 to 75 years;
Male smoker (≥400 cig/year), female smoker or non-smoker;
Visible lung nodule lesion in the chest (based on local CT result);
Without the indication of biopsy (bronchoscope or percutaneous transthoracic) or surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Suspected lung cancer group</arm_group_label>
    <description>Aged 40 to 75 years;
Male smoker (≥400 cig/year), female smoker or non-smoker;
Visible lung cancer lesion in the chest (based on local CT result);
With the indication of biopsy (bronchoscope or percutaneous transthoracic) or surgery.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      10mL blood sample of the patient will be tested for cancer biomarkers, biochemical detection
      and cardiovascular disease biomarkers, etc.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Totally 1,200 cases will be collected in the hospitals, with 600 cases in control group,
        which are not suspected as lung cancer from chest CT, and other 600 in suspected group.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-suspected lung cancer group (600 cases)

               1. Aged 40 to 75 years;

               2. Male smoker (≥400 cig/year), female smoker or non-smoker;

               3. Visible lung nodule lesion in the chest (based on local CT result);

               4. Without the indication of biopsy (bronchoscope or percutaneous transthoracic) or
                  surgery.

          -  Suspected lung cancer group (600 cases)

               1. Aged 40 to 75 years;

               2. Male smoker (≥400 cig/year), female smoker or non-smoker;

               3. Visible lung cancer lesion in the chest (based on local CT result);

               4. With the indication of biopsy (bronchoscope or percutaneous transthoracic) or
                  surgery.

        Exclusion Criteria:

          -  Histopathological diagnosis result is unavailable, including patients only have
             cytology results of pleural effusion;

          -  Already treated by chemotherapy or surgery
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chunxue Bai, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese Alliance Against Lung Cancer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chunxue Bai, Prof.</last_name>
    <phone>+86-18621170011</phone>
    <email>bai.chunxue@zs-hospital.sh.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qunying Hong, Dr.</last_name>
    <phone>+86-13816880830</phone>
    <email>hong.qunying@zs-hospital.sh.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Ni, Dr.</last_name>
      <phone>+86-13716173329</phone>
      <email>nijun666525@126.com</email>
    </contact>
    <investigator>
      <last_name>Li Zhang, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Third Military Medical University</name>
      <address>
        <city>Chongqing</city>
        <zip>400037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bin Wang, Dr.</last_name>
      <phone>+86-13996084288</phone>
      <email>wangbin985@126.com</email>
    </contact>
    <investigator>
      <last_name>Guoming Wu, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuehong Wang, Dr.</last_name>
      <phone>+86-13989826233</phone>
      <email>yuehongw@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Jianying Zhou, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nanjing PLA General Hospital</name>
      <address>
        <city>Nanjing</city>
        <zip>210002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianya Zhang, Dr.</last_name>
      <phone>+86-13913838392</phone>
      <email>zhangjianya_zjy@126.com</email>
    </contact>
    <investigator>
      <last_name>Yong Song, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dawei Yang, Dr.</last_name>
      <phone>+86 13564703813</phone>
      <email>yang_dw@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Chunxue Bai, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Qunying Hong, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henan Provincial Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <zip>450000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yafei Zhang, Dr.</last_name>
      <phone>+86-18236925562</phone>
      <email>fei.kai.happy@163.com</email>
    </contact>
    <investigator>
      <last_name>Xiaoju Zhang, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.calc-cn.org/en-us/research.aspx</url>
    <description>Official website of Chinese Alliance Against Lung Cancer</description>
  </link>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 12, 2014</lastchanged_date>
  <firstreceived_date>August 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Alliance Against Lung Cancer</investigator_affiliation>
    <investigator_full_name>Bai Chunxue</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>Carcinoma, Non-Small-Cell Lung</keyword>
  <keyword>Small Cell Lung Carcinoma</keyword>
  <keyword>Biological Markers</keyword>
  <keyword>ROC Curve</keyword>
  <keyword>Delayed Diagnosis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
